초록 ▼

Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive mole

Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFβ superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.

대표청구항 ▼

1. A method for improving healing of bony defect sites in a patient at a bony defect site in need thereof comprising administering to the site a composition consisting ofa fibrin matrix, anda non-glycosylated TGFβ superfamily growth factor that is capable of being glycosylated,wherein the non-glycos

1. A method for improving healing of bony defect sites in a patient at a bony defect site in need thereof comprising administering to the site a composition consisting ofa fibrin matrix, anda non-glycosylated TGFβ superfamily growth factor that is capable of being glycosylated,wherein the non-glycosylated growth factor is precipitated in the matrix in an effective amount to enhance healing of bony defects,wherein the growth factor enhances healing of bony defects at the site. 2. The method of claim 1 wherein the growth factor is a member of the bone morphogenic protein family. 3. The method of claim 2, wherein the growth factor is selected from the group consisting of rh-BMP-2 and rh-BMP-7. 4. The method of claim 3, wherein the growth factor is rh-BMP-2. 5. The method of claim 1, wherein the site is selected from the group consisting of treatment sites containing spinal fusion cages, bone augmentation sites, dental regeneration sites, and bone regeneration sites following trauma. 6. The method of claim 1, wherein at least 60% of the growth factor is retained in the matrix after 10 wash volumes. 7. The method of claim 1, wherein the growth factor is released to the site for up to four weeks following administration. 8. The method of claim 7, wherein the growth factor is released to the site for two to four weeks following administration. 9. A method for improving healing of bony defect sites in a patient at a bony defect site in need thereof comprising administering to the site a composition consisting of a first and a second precursor component required to form a fibrin matrix, and a non-glycosylated TGFβ superfamily growth factor that is capable of being glycosylated,wherein at least one of the precursor components contains the non-glycosylated growth factor,wherein the first and the second precursor components mix to form the matrix,wherein first precursor component contains fibrinogen and the second precursor component contains thrombin,wherein the non-glycosylated growth factor is precipitated in the matrix in an effective amount to enhance healing of bony defects, andwherein the growth factor enhances healing of bony defects at the site. 10. The method of claim 9, wherein the site is selected from the group consisting of treatment sites containing spinal fusion cages, bone augmentation sites, dental regeneration sites, and bone regeneration sites following trauma. 11. The method of claim 9, wherein the composition is administered to the site by injection. 12. The method of claim 9, wherein the growth factor is a member of the bone morphogenic protein family. 13. The method of claim 12, wherein the growth factor is selected from the group consisting of rh-BMP-2 and rh-BMP-7. 14. The method of claim 13, wherein the growth factor is rh-BMP-2.